Industry Satellite Symposia

This symposium is for healthcare professionals only, it is not open to patients or members of the public.

Thursday 6 June 2024

13:00–14:00 BST

(Clyde Auditorium)

Broadening treatment horizons for people with cystic fibrosis

Chaired by:
Prof. Jane Davies, Imperial College London, UK 

Prof. Marcus Mall, Charité – Universitätsmedizin Berlin, Germany 
Prof. Pierre Regis Burgel, Université Paris-Cité, France 
Dr Patrick Sosnay & Dr Fred Van Goor, Vertex Pharmaceuticals, USA


Chair’s opening remarks:
Continuing the drive for innovative care in CF

Prof. Jane Davies  


CFTR function restoration:
How much is enough?

Prof. Marcus Mall
Dr Patrick Sosnay 


Rare mutations:
Approaches to assessing response to CFTR modulation

Prof. Pierre Regis Burgel
Dr Fred Van Goor 


The remaining 7%:
The journey of innovation continues

Prof. Jane Davies
Dr Fred Van Goor 


Chair’s closing remarks

Prof. Jane Davies  

There will be the opportunity for questions throughout the symposium.

•    Discuss the importance of restoring CFTR function
•    Describe the challenges in developing therapies for pwCF with rare mutations
•    Highlight current and future therapy innovations to potentially reach all pwCF

Friday 7 June 2024

07:45 – 08:45  BST

Hall 1

What respiratory endpoints will be used to monitor CF patients with a CFTR-related disorder, specifically in older age groups, and what are the challenges?

Gopal Allada MD
Associate Professor of Medicine, Oregon Health and Science University
Director: Adult Cystic Fibrosis Program

Carl Mottram
Associate Professor of Medicine
Chief Scientific Advisor, Vitalograph LTD

Dr. Allada will review adult Cystic Fibrosis patients with a CFTR-related disorder and some of the challenges this diagnosis presents in late onset identification versus traditional “cystic fibrosis” patients which present with early onset of symptoms.   Dr. Allada will present patient cases in an interactive session, with audience participation, to elicit discussion and gather clinical opinions on this unique patient population. He will also discuss a proposed follow up paradigm for these patients, highlighting information from the 2022 European Cystic Fibrosis Guidelines.  These patients tend to have mild or even absent lung disease which may potentially be identified and followed with the measurement of Lung Clearance Index (LCI) and other lung function parameters.  

Professor Mottram will review recent literature related to LCI and spirometry testing including what challenges are present in performing these tests, new technical standards on testing, and current evidence related to home testing.

This symposium is for healthcare professionals only, it is not open to patients or members of the public.

Friday 7 June 2024

13:00–14:00 BST

(Clyde Auditorium)

Adapting to the new era for people with cystic fibrosis

Chaired by:
Prof. Isabelle Fajac, Université de Paris, France 

Dr Florian Stehling, Universitätsklinikum Essen, Germany 
Dr Eva Polverino, University Hospital Vall d’Hebron, Barcelona, Spain
Dr Andrea Gramegna, Università degli Studi di Milano, Italy 


Chair’s opening remarks:
Evaluating the CF journey so far

Prof. Isabelle Fajac 


Setting new standards for the paediatric CF population

Dr Florian Stehling


Impact of longer life:
Holistic care for the older adult

Dr Eva Polverino


Ensuring all patients are on the journey:
Management approaches for patients ineligible for CFTR modulator therapy

Dr Andrea Gramegna


Q&A and Chair’s closing remarks

All speakers, 
Prof. Isabelle Fajac

•    Provide an overview of the achievements of the CF clinical community, underscored by improvements to CFTR function 
•    Educate on the importance of treating early and the impact this has on CFTR function and extrapulmonary outcomes
•    Highlight the need for alternative approaches to monitor clinical outcomes
•    Raise awareness of the areas of unmet need in the care of pwCF, including the need for holistic care of ageing adults living with CF, and appropriate management for pwCF who are ineligible for current treatment options

The 45th European Cystic Fibrosis Conference has been assessed as compliant by EthicalMedTech.
Please view the assessment details: click here


Thursday 6 June 2024
16:30-17:00 BST

 ePoster Corner B (M3)

Simeox therapy Clinical Evidence in Cystic Fibrosis

•    Simeox sputum clearance device: why and how
•    Review of data from peer-reviewed publications
•    Questions & Answers

Presenter: Laurent Morin, PhD, Medical Affairs Director (Physio-Assist)